Rescue of deficient amygdala tonic γ-aminobutyric acidergic currents in the Fmr-/y mouse model of fragile X syndrome by a novel γ-aminobutyric acid type A receptor-positive allosteric modulator

Journal of Neuroscience Research

Volumn 94, Issue 6, 2016, Pages 568-578

  Martin, Brandon S ^a   Martinez Botella, Gabriel ^b   Loya, Carlos M ^b   Salituro, Francesco G ^b   Robichaud, Albert J ^b   Huntsman, Molly M ^c   Ackley, Mike A ^b   Doherty, James J ^b   Corbin, Joshua G ^a  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b Sage Therapeutics Inc   (United States)

^c University of Colorado Denver and Children s Hospital Colorado   (United States)

Author keywords

Amygdala; Fragile X syndrome; GABA; GABAA receptor; Positive allosteric modulator

Indexed keywords

3 AMINO 2 (3 CARBOXYPROPYL) 6 (4 METHOXYPHENYL)PYRIDAZINIUM BROMIDE; 3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; 4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID A RECEPTOR BLOCKING AGENT; RECEPTOR; SGE 872; UNCLASSIFIED DRUG; 4 AMINOBUTYRIC ACID; BENZODIAZEPINE RECEPTOR AFFECTING AGENT; ELTANOLONE; FMR1 PROTEIN, MOUSE; FRAGILE X MENTAL RETARDATION PROTEIN; FUSED HETEROCYCLIC RINGS; GABAERGIC RECEPTOR AFFECTING AGENT; SGE-872;

AMYGDALOID NUCLEUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN SLICE; COMPARATIVE STUDY; CONTROLLED STUDY; CURRENT DENSITY; DRUG EFFICACY; FRAGILE X SYNDROME; GABAERGIC TRANSMISSION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SYNAPTIC EFFICACY; WHOLE CELL PATCH CLAMP; AMYGDALA; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; CHO CELL LINE; CRICETULUS; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; GENETIC TRANSFECTION; GENETICS; IN VITRO STUDY; KNOCKOUT MOUSE; MEMBRANE POTENTIAL; METABOLISM; NEWBORN; PATCH CLAMP TECHNIQUE; PATHOLOGY;

AMYGDALA; ANIMALS; ANIMALS, NEWBORN; CHO CELLS; CRICETULUS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; GABA AGENTS; GABA MODULATORS; GAMMA-AMINOBUTYRIC ACID; HETEROCYCLIC COMPOUNDS, 2-RING; IN VITRO TECHNIQUES; MEMBRANE POTENTIALS; MICE; MICE, KNOCKOUT; PATCH-CLAMP TECHNIQUES; PREGNANOLONE; RECEPTORS, GABA-A; TRANSFECTION;

EID: 84940703524     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.23632     Document Type: Article

References (68)

1. Amaral DG, Bauman MD, Schumann CM. 2003. The amygdala and autism: implications from nonhuman primate studies. Genes Brain Behav 2:295-302.
2. Bäckström T, Bixo M, Johansson M, Nyberg S, Ossewaarde L, Ragagnin G, Savic I, Strömberg J, Timby E, van Broekhoven F, van Wingen G. 2014. Allopregnanolone and mood disorders. Prog Neurobiol 113:88-94.
3. Barker JL, Harrison NL, Lange GD, Owen DG. 1987. Potentiation of gamma-aminobutyric-acid-activated chloride conductance by a steroid anaesthetic in cultured rat spinal neurones. J Physiol 386:485-501.
4. Baron-Cohen S, Ring HA, Bullmore ET, Wheelwright S, Ashwin C, Williams SC. 2000. The amygdala theory of autism. Neurosci Biobehav Rev 24:355-364.
5. Bear MF, Huber KM, Warren ST. 2004. The mGluR theory of fragile X mental retardation. Trends Neurosci 27:370-377.
6. A receptor. Nat Rev Neurosci 6:565-575.
7. A receptors. Neuropharmacology 43:651-661.
8. A receptors regulate the intrinsic excitability of mouse hippocampal pyramidal neurons. J Neurophysiol 98:2244-2254.
9. A receptors: their function in the CNS and implications for disease. Neuron 73:23-34.
10. A receptors. J Physiol 497:753-759.
11. Brickley SG, Revilla V, Cull-Candy SG, Wisden W, Farrant M. 2001. Adaptive regulation of neuronal excitability by a voltage-independent potassium conductance. Nature 409:88-92.
12. A receptors. Br J Pharmacol 136:965-974.
13. Carter RB, Wood PL, Wieland S, Hawkinson JE, Belelli D, Lambert JJ, White HS, Wolf HH, Mirsadeghi S, Tahir SH, Bolger MB, Lan NC, Gee KW. 1997. Characterization of the anticonvulsant properties of ganaxolone (CCD 1042; 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one), a selective, high-affinity, steroid modulator of the gamma-aminobutyric acid(A) receptor. J Pharmacol Exp Ther 280:1284-1295.
14. A receptors: regulation of subunit plasticity, phasic and tonic inhibition, and neuronal network excitability. Psychopharmacology 230:151-188.
15. Chao H-T, Chen H, Samaco RC, Xue M, Chahrour M, Yoo J, Neul JL, Gong S, Lu H-C, Heintz N, Ekker M, Rubenstein JLR, Noebels JL, Rosenmund C, Zoghbi HY. 2010. Dysfunction in GABA signalling mediates autism-like stereotypes and Rett syndrome phenotypes. Nature 468:263-269.
16. Curia G, Papouin T, Séguéla P, Avoli M. 2009. Downregulation of tonic GABAergic inhibition in a mouse model of fragile X syndrome. Cereb Cortex 19:1515-1520.
17. Dalby B, Cates S, Harris A, Ohki EC, Tilkins ML, Price PJ, Ciccarone VC. 2004. Advanced transfection with Lipofectamine 2000 reagent: primary neurons, siRNA, and high-throughput applications. Methods 33:95-103.
18. A receptor in fragile X syndrome. Brain Res 1121:238-245.
19. A receptor-mediated conductance in mouse neocortex. Cereb Cortex 16:1134-1141.
20. Ehrlich I, Humeau Y, Grenier F, Ciocchi S, Herry C, Lüthi A. 2009. Amygdala inhibitory circuits and the control of fear memory. Neuron 62:757-771.
21. A receptors. Nat Rev Neurosci 6:215-229.
22. BR1 receptors are altered in brains from subjects with autism. J Autism Dev Disord 40:743-750.
23. A receptor protein subunits α6, β2, δ, ε, γ2, θ, and ρ2 in superior frontal cortex of subjects with autism. J Autism Dev Disord. 44:1833-1845.
24. Fries P. 2009. Neuronal gamma-band synchronization as a fundamental process in cortical computation. Annu Rev Neurosci 32:209-224.
25. A receptor subunit delta in the fragile X knockout mouse model. Neurobiol Dis 21:346-357.
26. Geschwind DH, Levitt P. 2007. Autism spectrum disorders: developmental disconnection syndromes. Curr Opin Neurobiol 17:103-111.
27. Gibson JR, Bartley AF, Hays SA, Huber KM. 2008. Imbalance of neocortical excitation and inhibition and altered UP states reflect network hyperexcitability in the mouse model of fragile X syndrome. J Neurophysiol 100:2615-2626.
28. Glykys J, Mody I. 2007. The main source of ambient GABA responsible for tonic inhibition in the mouse hippocampus. J Physiol 582:1163-1178.
29. Gonçalves JT, Anstey JE, Golshani P, Portera-Cailliau C. 2013. Circuit level defects in the developing neocortex of fragile X mice. Nat Neurosci 16:903-909.
30. +/- mice and rescue by enhanced GABA-mediated neurotransmission. Nature 489:385-390.
31. Han S, Tai C, Jones CJ, Scheuer T, Catterall WA. 2014. Enhancement of inhibitory neurotransmission by GABA. Neuron 81:1282-1289.
32. A channel subtypes. Mol Neurobiol 18:35-86.
33. A receptors. Neuropharmacology 58:702-711.
34. Huntsman MM, Porcello DM, Homanics GE, DeLorey TM, Huguenard JR. 1999. Reciprocal inhibitory connections and network synchrony in the mammalian thalamus. Science 283:541-543.
35. A receptor mediates tonic inhibition in thalamic VB neurons. J Neurophysiol 94:4491-4501.
36. Krook-Magnuson EI, Li P, Paluszkiewicz SM, Huntsman MM. 2008. Tonically active inhibition selectively controls feed-forward circuits in mouse barrel cortex. J Neurophysiol 100:932-944.
37. A receptor subunits associated with genetic epilepsies. J Physiol 588:1861-1869.
38. A receptors mediating tonic inhibition alter seizure susceptibility and anxiety. Nat Neurosci 8:797-804.
39. A receptor. Mechanism of action and physiological significance. Prog Neurobiol 38:379-395.
40. Maldonado-Avilés JG, Curley AA, Hashimoto T, Morrow AL, Ramsey AJ, O'Donnell P, Volk DW, Lewis DA. 2009. Altered markers of tonic inhibition in the dorsolateral prefrontal cortex of subjects with schizophrenia. Am J Psychiatry 166:450-459.
41. Mann EO, Mody I. 2010. Control of hippocampal gamma oscillation frequency by tonic inhibition and excitation of interneurons. Nat Neurosci 13:205-212.
42. Markram K, Markram H. 2010. The intense world theory: a unifying theory of the neurobiology of autism. Front Hum Neurosci 4:224.
43. A receptors. J Neurosci 32:8611-8619.
44. Martin BS, Corbin JG, Huntsman MM. 2014. Deficient tonic GABAergic conductance and synaptic balance in the fragile-X syndrome amygdala. J Neurophysiol 112: 890-902.
45. A receptor activity sets the threshold for long-term potentiation and constrains hippocampus-dependent memory. J Neurosci 30:5269-5282.
46. Mitchell SJ, Silver RA. 2003. Shunting inhibition modulates neuronal gain during synaptic excitation. Neuron 38:433-445.
47. A receptors. Trends Neurosci 27:569-575.
48. Olmos-Serrano JL, Paluszkiewicz SM, Martin BS, Kaufmann WE, Corbin JG, Huntsman MM. 2010. Defective GABAergic neurotransmission and pharmacological rescue of neuronal hyperexcitability in the amygdala in a mouse model of fragile X syndrome. J Neurosci 30:9929-9938.
49. A receptor agonist THIP ameliorates specific behavioral deficits in the mouse model of fragile X syndrome. Dev Neurosci 33:395-403.
50. Paluszkiewicz SM, Martin BS, Huntsman MM. 2011. Fragile X syndrome: the GABAergic system and circuit dysfunction. Dev Neurosci 33:349-364.
51. Pinna G. 2014. Targeting neurosteroidogenesis as therapy for PTSD. Front Pharmacol 4:166.
52. A receptors: immunocytochemical distribution of 13 subunits in the adult rat brain. Neuroscience 101:815-850.
53. Pizzarelli R, Cherubini E. 2011. Alterations of GABAergic signaling in autism spectrum disorders. Neural Plasticity 2011:297153.
54. Reddy DS, Rogawski MA. 2009. Neurosteroid replacement therapy for catamenial epilepsy. Neurotherapeutics 6:392-401.
55. Rossi DJ, Hamann M, Attwell D. 2003. Multiple modes of GABAergic inhibition of rat cerebellar granule cells. J Physiol 548:97-110.
56. Rudolph U, Mohler H. 2014. GABAA receptor subtypes: therapeutic potential in Down syndrome, affective disorders, schizophrenia, and autism. Annu Rev Pharmacol Toxicol 54:483-507.
57. Sah P, Faber ESL, Lopez De Armentia M, Power J. 2003. The amygdaloid complex: anatomy and physiology. Physiol Rev 83:803-834.
58. Schüle C, Nothdurfter C, Rupprecht R. 2014. The role of allopregnanolone in depression and anxiety. Prog Neurobiol 113:79-87.
59. Semyanov A, Walker MC, Kullmann DM, Silver RA. 2004. Tonically active GABA A receptors: modulating gain and maintaining the tone. Trends Neurosci 27:262-269.
60. A receptors. Proc Natl Acad Sci U S A 100:14439-14444.
61. A receptors: functional selectivity for extrasynaptic receptors is dependent on the absence of gamma2. J Pharmacol Exp Ther 316:1351-1359.
62. Testa-Silva G, Loebel A, Giugliano M, de Kock CPJ, Mansvelder HD, Meredith RM. 2012. Hyperconnectivity and slow synapses during early development of medial prefrontal cortex in a mouse model for mental retardation and autism. Cereb Cortex 22:1333-1342.
63. Vislay RL, Martin BS, Olmos-Serrano JL, Kratovac S, Nelson DL, Corbin JG, Huntsman MM. 2013. Homeostatic responses fail to correct defective amygdala inhibitory circuit maturation in fragile X syndrome. J Neurosci 33:7548-7558.
64. Wafford KA, Ebert B. 2006. Gaboxadol-a new awakening in sleep. Curr Opin Pharmacol 6:30-36.
65. Wafford KA, Ebert B. 2008. Emerging anti-insomnia drugs: tackling sleeplessness and the quality of wake time. Nat Rev Drug Discov 7:530-540.
66. Wafford KA, van Niel MB, Ma QP, Horridge E, Herd MB, Peden DR, Belelli D, Lambert JJ. 2009. Neuropharmacology. Neuropharmacology 56:182-189.
67. A receptors containing the delta subunit. J Neurosci 22:1541-1549.
68. Zoghbi HY. 2003. Postnatal neurodevelopmental disorders: meeting at the synapse? Science 302:826-830.